Evidence map›Paper›PMID 30224341›Full record

Trial reportClinical cancer research : an official journal of the American Association for Cancer Research2019

MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.

Aparna R Parikh, Fa-Chyi Lee, Linda Yau, Han Koh, James Knost, Edith P Mitchell, Ivan Bosanac, Nicholas Choong, Frank Scappaticci, Christoph Mancao and 1 more

Abstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical cancer research : an official journal of the American Association for Cancer Research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 8 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 8 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Randomized, Phase II Study Prospectively Evaluating Treatment of Metastatic Esophageal, Gastric, or Gastroesophageal Cancer by Gene Expression ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020
    Trial
  12. Article
  13. The Current Role of Antiangiogenics in Colorectal Cancer.International journal of molecular sciences · 2025
    Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Aparna R ParikhDivision of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts. Aparna.Parikh@MGH.HARVARD.EDU.
Fa-Chyi LeeDivision of Hematology/Oncology, University of California Irvine, Irvine, California.
Linda YauEvidence Generation, Biometrics, Genentech, Inc., US Medical Affairs, South San Francisco, California.
Han KohDepartment of Medical Oncology, Southern California Permanente Group, Bellflower, California.
James KnostDepartment of Hematology/Oncology, Illinois Cancer Center, Peoria, Illinois.
Edith P MitchellSidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.
Ivan BosanacGlobal Product Development Medical Affairs-PDMA, F. Hoffmann-La Roche, Basel, Switzerland.
Nicholas ChoongGenentech, Inc., US Medical Affairs, South San Francisco, California.
Frank ScappaticciBioOncology, Genentech, Inc., US Medical Affairs, South San Francisco, California.
Christoph MancaoOncology Biomarker Development, Genentech Inc., Basel, Switzerland.
Heinz-Josef LenzNorris Comprehensive Cancer Center, Keck School of Medicine, Department of Medicine, University of Southern California, Los Angeles, California.

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
NCI NIH HHS P30 CA014089
6 · The paper itself

Abstract

purposeMAVERICC compared the efficacy and safety of modified leucovorin/5-fluorouracil/oxaliplatin plus bevacizumab (mFOLFOX6-BV) with leucovorin/5-fluorouracil/irinotecan plus bevacizumab (FOLFIRI-BV) in patients with previously untreated metastatic colorectal cancer (mCRC).

resultsOf 376 enrolled patients, 188 each received mFOLFOX6-BV and FOLFIRI-BV. PFS and overall survival (OS) were comparable between FOLFIRI-BV and mFOLFOX6-BV, with numerically higher PFS [HR = 0.79; 95% CI (confidence interval): 0.61-1.01;

conclusionsFirst-line FOLFIRI-BV and mFOLFOX6-BV had comparable PFS and OS, similar to results in patients with high baseline tumor ERCC1 levels. There were no new safety signals with these bevacizumab-containing regimens.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBevacizumabBiomarkers, TumorCamptothecinColorectal NeoplasmsDNA-Binding ProteinsEndonucleasesFemaleFluorouracilHumansIrinotecanLeucovorinMaleBevacizumabBiomarkers, TumorCamptothecinDNA-Binding ProteinsEndonucleasesERCC1 protein, humanFluorouracilIrinotecanLeucovorinOrganoplatinum CompoundsVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID30224341
PMCPMC9022943

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.